Shots:
- The US FDA has accepted IND application of DMX-1001 (oral noribogaine) for the treatment of alcohol use disorder (AUD)
- DemeRx completed a MAD trial of DMX-1001 in healthy volunteers, demonstrating safety, tolerability, & PK supportive of P-II in AUD. The company plans to initiate a P-II trial of DMX-1001 in AUD in 2027
- Noribogaine is a long-acting metabolite of ibogaine that persists longer in the body, promoting sustained neuroplastic changes to help repair neural circuits damaged by chronic substance abuse
Ref: Businesswire | Image: DemeRx | Press Release
Related News: Henlius Receives NMPA IND Clearance for HLX05-N (Biosimilar, Erbitux)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
